Oxyphenbutazone
Tandearil (oxyphenbutazone) is a small molecule pharmaceutical. Oxyphenbutazone was first approved as Tandearil on 1982-09-03.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxyphenbutazone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TANDEARIL | Novartis | N-012542 DISCN | 1982-09-03 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AA: Butylpyrazolidines, antiinflammatory and antirheumatic drugs
— M01AA03: Oxyphenbutazone
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AA: Antiinflammatory preparations, non-steroids for topical use
— M02AA04: Oxyphenbutazone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BC: Antiinflammatory agents, non-steroidal, ophthalmologic
— S01BC02: Oxyphenbutazone
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 1 | 1 | 1 | — | 3 |
| Candidiasis | D002177 | B37 | — | — | — | 1 | 1 | 2 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
| Mycoses | D009181 | B35-B49 | — | — | — | 1 | — | 1 | |
| Vaginitis | D014627 | EFO_0005757 | N76 | — | — | — | 1 | — | 1 |
| Critical illness | D016638 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | 1 | — | 4 | 7 |
| Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | — | 2 | — | 3 | 5 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 1 | 1 | — | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | 1 | — | — | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | 1 | — | — | 1 | |
| Leukemia | D007938 | C95 | — | — | 1 | — | — | 1 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | 1 | — | — | 1 | |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 1 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | 1 | — | — | 1 | |
| Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental caries | D003731 | EFO_0003819 | K02 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OXYPHENBUTAZONE |
| INN | oxyphenbutazone |
| Description | Oxyphenbutazone is a metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic, a gout suppressant, a drug metabolite, a xenobiotic metabolite, an antineoplastic agent and an antimicrobial agent. It is a member of pyrazolidines and a member of phenols. It is functionally related to a phenylbutazone. |
| Classification | Small molecule |
| Drug class | anti-inflammatory analgesics (phenylbutazone type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O |
Identifiers
| PDB | — |
| CAS-ID | 129-20-4 |
| RxCUI | 7816 |
| ChEMBL ID | CHEMBL3989676 |
| ChEBI ID | — |
| PubChem CID | 4641 |
| DrugBank | DB03585 |
| UNII ID | A7D84513GV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 600 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,803 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more